Diagnostic yield of screening colonoscopy in Hodgkin lymphoma survivors
- Conditions
- adenomasneoplasiapolyps1001799010017987
- Registration Number
- NL-OMON44361
- Lead Sponsor
- Antoni van Leeuwenhoek Ziekenhuis
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 259
• HL diagnosis at the age of 16-50 years
• Treatment for HL between 1965 and 2007
• Treatment of primary or recurrent HL consisting of
o infradiaphragmatic radiotherapy (any field(s)) and chemotherapy (any regimen)
and/or
o infradiaphragmatic radiotherapy consisting of at least para-aortal and iliac fields
and/or
o chemotherapy containing a cumulative procarbazine dose of >=2.8 g/m2
(e.g. >=2 MOPP, >=4 BEACOPP or >=4 MOPP/ABV courses)
• Survival of at least 8 years after the first treatment that included infradiaphragmatic radiotherapy and chemotherapy or procarbazine-containing chemotherapy
• Age of 25 years or older
• Life expectancy of five years or more
• Proctocolectomy
• Colonoscopy surveillance for other indications (including hereditary CRC syndrome, familial CRC syndrome, inflammatory bowel disease, history of colorectal adenoma or CRC)
• Colonoscopy in the past five years
• On-going cytotoxic treatment or radiotherapy for malignant disease
• Coagulopathy (prothrombin time < 50% of control; partial thromboplastin time > 50 seconds) or anticoagulants (marcoumar, acenocoumarol or new oral anticoagulants) that cannot be stopped
• Comorbidity leading to an impaired physical performance (World health organization (WHO) performance status 3-4) or mental retardation
• No informed consent
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>- Diagnostic yield of advanced colorectal neoplasia detected by a colonoscopy</p><br>
- Secondary Outcome Measures
Name Time Method <p>- Molecular characteristics of advanced colorectal neoplasia<br /><br>- The relation of neoplasia characteristics to radiotherapy and / or<br /><br>chemotherapy<br /><br>- The cost-effectiveness of colonoscopy screening<br /><br>- The burden of colonoscopy screening<br /><br>- Performance of fecal immunochemical test and molecular stool test<br /><br>- The development of CRC surveillance guidelines for HL survivors</p><br>